Marie-Claude Geoffroy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marie-Claude Geoffroy has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Hugues de Thé
Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 1 , Equipe Labellisée par la Ligue contre le Cancer, Paris
5 shared publications - Michiko Niwa-Kawakita
Université Paris Cité, Inserm, CNRS, GenCellDis, Institut de Recherche Saint-Louis, Paris, France
5 shared publications - Valérie Lallemand-Breitenbach
Center for Interdisciplinary Research in Biology (CIRB), Collège de France, PSL research university, Inserm, Cnrs, Paris, France
3 shared publications Alfred C. O. Vertegaal
Department of Cell and Chemical Biology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
2 shared publications- Antoine Canat
Université Paris Cité, Inserm, CNRS, GenCellDis, Institut de Recherche Saint-Louis, Paris, France
2 shared publications - Cécile Esnault
Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 1 , Equipe Labellisée par la Ligue contre le Cancer, Paris
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Correction: PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization
- 22 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Open AccessCorrection: PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization
- Open Access
- 28 August 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization
While acute promyelocytic leukemia (APL) is always driven by fusions involving one of the three retinoic acid receptors, why PML and RARA are the preferred fusion partners has remained largely unsettled. Here, we demonstrate that corepressor (NCoR) binding onto the RARA moiety of PML::RARA is required for hematopoietic progenitor immortalization. We establish that PML-mediated tethering of the UBC9 SUMO-conjugating enzyme onto PML::RARA enforces SUMO2 conjugation of multiple RARA partner proteins, notably the NCoR complex, boosting its repressive power. PML mutants that fail to recruit UBC9 yield PML::RARA fusions that promote neither NCoR sumoylation nor transformation. Conversely, direct UBC9/RARA fusion drives both efficient corepressor complex sumoylation and immortalization. Sumoylation inhibitors reactivate retinoic acid target genes in PML::RARA-expressing, but not in RARA-expressing, progenitors and trigger APL differentiation. Thus, fusion of PML to RARA entails an unexpected gain of function that boosts RARA-mediated transcriptional repression through sumoylation of PML::RARA-bound proteins, explaining the recurrent implication of PML and RARA in APL pathogenesis.
- 28 August 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
Open AccessPML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization
While acute promyelocytic leukemia (APL) is always driven by fusions involving one of the three retinoic acid receptors, why PML and RARA are the preferred fusion partners has remained largely unsettled. Here, we demonstrate that corepressor (NCoR) binding onto the RARA moiety of PML::RARA is required for hematopoietic progenitor immortalization. We establish that PML-mediated tethering of the UBC9 SUMO-conjugating enzyme onto PML::RARA enforces SUMO2 conjugation of multiple RARA partner proteins, notably the NCoR complex, boosting its repressive power. PML mutants that fail to recruit UBC9 yield PML::RARA fusions that promote neither NCoR sumoylation nor transformation. Conversely, direct UBC9/RARA fusion drives both efficient corepressor complex sumoylation and immortalization. Sumoylation inhibitors reactivate retinoic acid target genes in PML::RARA-expressing, but not in RARA-expressing, progenitors and trigger APL differentiation. Thus, fusion of PML to RARA entails an unexpected gain of function that boosts RARA-mediated transcriptional repression through sumoylation of PML::RARA-bound proteins, explaining the recurrent implication of PML and RARA in APL pathogenesis.
- Open Access
- 1 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2548-2565
Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
PML nuclear bodies (NB) are disrupted in PML-RARA–driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation. In non-APL cells, arsenic binding onto PML also amplifies NB formation. Yet, the actual molecular mechanism(s) involved remain(s) elusive. Here, we establish that PML NBs display some features of liquid–liquid phase separation and that ATO induces a gel-like transition. PML B-box-2 structure reveals an alpha helix driving B2 trimerization and positioning a cysteine trio to form an ideal arsenic-binding pocket. Altering either of the latter impedes ATO-driven NB assembly, PML sumoylation, and PML-RARA degradation, mechanistically explaining clinical ATO resistance. This B2 trimer and the C213 trio create an oxidation-sensitive rheostat that controls PML NB assembly dynamics and downstream signaling in both basal state and during stress response. These findings identify the structural basis for arsenic targeting of PML that could pave the way to novel cancer drugs. Significance: Arsenic curative effects in APL rely on PML targeting. We report a PML B-box-2 structure that drives trimer assembly, positioning a cysteine trio to form an arsenic-binding pocket, which is disrupted in resistant patients. Identification of this ROS-sensitive triad controlling PML dynamics and functions could yield novel drugs. See related commentary by Salomoni, p. 2505. This article is featured in Selected Articles from This Issue, p. 2489
- 1 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2548-2565
Open AccessStructural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
PML nuclear bodies (NB) are disrupted in PML-RARA–driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation. In non-APL cells, arsenic binding onto PML also amplifies NB formation. Yet, the actual molecular mechanism(s) involved remain(s) elusive. Here, we establish that PML NBs display some features of liquid–liquid phase separation and that ATO induces a gel-like transition. PML B-box-2 structure reveals an alpha helix driving B2 trimerization and positioning a cysteine trio to form an ideal arsenic-binding pocket. Altering either of the latter impedes ATO-driven NB assembly, PML sumoylation, and PML-RARA degradation, mechanistically explaining clinical ATO resistance. This B2 trimer and the C213 trio create an oxidation-sensitive rheostat that controls PML NB assembly dynamics and downstream signaling in both basal state and during stress response. These findings identify the structural basis for arsenic targeting of PML that could pave the way to novel cancer drugs. Significance: Arsenic curative effects in APL rely on PML targeting. We report a PML B-box-2 structure that drives trimer assembly, positioning a cysteine trio to form an arsenic-binding pocket, which is disrupted in resistant patients. Identification of this ROS-sensitive triad controlling PML dynamics and functions could yield novel drugs. See related commentary by Salomoni, p. 2505. This article is featured in Selected Articles from This Issue, p. 2489
- Open Access
- 9 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells
- 9 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells
- Open Access
- 29 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells
Membrane-less organelles are condensates formed by phase separation whose functions often remain enigmatic. Upon oxidative stress, PML scaffolds Nuclear Bodies (NBs) to regulate senescence or metabolic adaptation. PML NBs recruit many partner proteins, but the actual biochemical mechanism underlying their pleiotropic functions remains elusive. Similarly, PML role in embryonic stem cell (ESC) and retro-element biology is unsettled. Here we demonstrate that PML is essential for oxidative stress-driven partner SUMO2/3 conjugation in mouse ESCs (mESCs) or leukemia, a process often followed by their poly-ubiquitination and degradation. Functionally, PML is required for stress responses in mESCs. Differential proteomics unravel the KAP1 complex as a PML NB-dependent SUMO2-target in arsenic-treated APL mice or mESCs. PML-driven KAP1 sumoylation enables activation of this key epigenetic repressor implicated in retro-element silencing. Accordingly, Pml−/− mESCs re-express transposable elements and display 2-Cell-Like features, the latter enforced by PML-controlled SUMO2-conjugation of DPPA2. Thus, PML orchestrates mESC state by coordinating SUMO2-conjugation of different transcriptional regulators, raising new hypotheses about PML roles in cancer.
- 29 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessExploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells
Membrane-less organelles are condensates formed by phase separation whose functions often remain enigmatic. Upon oxidative stress, PML scaffolds Nuclear Bodies (NBs) to regulate senescence or metabolic adaptation. PML NBs recruit many partner proteins, but the actual biochemical mechanism underlying their pleiotropic functions remains elusive. Similarly, PML role in embryonic stem cell (ESC) and retro-element biology is unsettled. Here we demonstrate that PML is essential for oxidative stress-driven partner SUMO2/3 conjugation in mouse ESCs (mESCs) or leukemia, a process often followed by their poly-ubiquitination and degradation. Functionally, PML is required for stress responses in mESCs. Differential proteomics unravel the KAP1 complex as a PML NB-dependent SUMO2-target in arsenic-treated APL mice or mESCs. PML-driven KAP1 sumoylation enables activation of this key epigenetic repressor implicated in retro-element silencing. Accordingly, Pml−/− mESCs re-express transposable elements and display 2-Cell-Like features, the latter enforced by PML-controlled SUMO2-conjugation of DPPA2. Thus, PML orchestrates mESC state by coordinating SUMO2-conjugation of different transcriptional regulators, raising new hypotheses about PML roles in cancer.